Oncolytic Virus Therapy
Oncolytic virus therapy uses a modified virus that can cause tumor cells to self-destruct and generate a greater immune response against the cancer.
A phase I/II trial of PexaVec (JX-594), a virus engineered to secrete GM-CSF and delete a kinase gene that is typically seen on cancer cells with a mutated RAS or p53 pathway, for patients with soft tissue sarcoma (NCT02630368).
A phase I/II trial to test talimogene laherparepvec (Imlygic™, T-VEC for short), a modified version of the herpes simplex virus I, the virus that causes cold sores, and radiation in patients with soft tissue sarcoma (NCT02453191).
A phase II trial of Poly-ICLC (Hiltonol®), a Toll-like receptor 3 agonist, for patients with select cancers, including sarcoma (NCT02423863). - See more at: http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/sarcoma#sthash.IW7r8NE2.dpuf
- See more at: http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/sarcoma#sthash.dUseCr6b.dpuf
Review of vaccine and immunotherapy for sarcomas from sarcoma help.
A phase I trial of CMB305 in patients with locally advanced, relapsed, or metastatic cancer that expresses NY-ESO-1, including sarcoma (NCT02387125).
A phase I trial of DSP-7888, which targets the WT1 marker, for patients with select cancers, including sarcoma (NCT02498665).
A dendritic cell vaccine is in a phase I trial for adults and children with sarcoma (soft tissue and bone) (NCT01803152).- See more at: http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/sarcoma#sthash.IW7r8NE2.dpuf
No comments:
Post a Comment